Gilead and Kite to present latest cell therapy research at the 25th European Hematology Association Virtual Congress
- Gilead Sciences, Inc. and Kite, a Gilead Company, are pleased to support the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress, taking place 11–21 June 2020.
- The EHA Annual Congress provides a key platform for haematologists from across Europe and around the world to increase their knowledge of evidence-based approaches for haematologic diseases, access the latest results on clinical and translational research in haematologic disorders and further understand emerging innovative techniques, diagnostic tools and risk-assessment strategies in haematology and its subspecialties.
- Gilead and Kite will be presenting scientific and real-world data from their cell therapy research programmes to attending healthcare professionals.
“We are pleased to be supporting the virtual edition of the EHA Congress 2020 and look forward to engaging, collaborating and sharing new data with haematologists throughout Europe and around the world.” said Dick Sundh, Vice President, Head of Europe, Kite. “Our presentations at this invaluable international meeting form part of our ongoing commitment to realising the full potential of cell therapy through continued research in advanced blood cancers.”
Presentations at the congress will include:
|
Presentation Number and Date/Time (CEST) |
Abstract Title |
|
Abstract #EP1259 (e-poster) Friday 12 June 2020 08:00 – 23:59 |
Retreatment of patients with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1 – F. Locke, Moffitt Cancer Center, Tampa, FL, USA |
|
Abstract #EP1763 (e-poster) Friday 12 June 2020 08:00 – 23:59 |
Axicabtagene ciloleucel for the management of patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma: an economic evaluation for Spain – M. Presa, Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain |
|
Abstract #EP1731 (e-poster) Friday 12 June 2020 08:00 – 23:59 |
Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US – J. Thornton Snider, Kite, a Gilead Company, Santa Monica, CA, USA |
|
Abstract #S144 (oral) Saturday 13 June 2020 08:00 – 23:59 |
The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: Phase 1b results – N. Daver, MD Anderson Cancer Center, Houston, TX, USA |
|
Abstract #S287 (oral) Sunday 14 June 2020 08:00 – 23:59 |
Interim analysis of ZUMA-5: A Phase 2 study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) – C.A. Jacobson, Dana-Farber Cancer Institute, Boston, MA, USA |
|
Abstract #S187 (oral) Sunday 14 June 2020 08:00 – 23:59 |
The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: Phase 1b results – D. Sallman, Moffitt Cancer Center, Tampa, FL, USA |
The following experts from Kite will be available for comments:
- Dick Sundh, Vice President, Head of Europe, Kite
- Bethany Dudek, Executive Director, Quality Head Europe, Kite
- Anne Kerber, Vice President, Head Clinical Development EU, Kite
For more information, or to request an interview please contact Cressida Robson, Media (Europe), Kite (+44 7341 789 204 or Cressida.Robson@kitepharma.com).
Editor Details
-
Company:
- Gilead and Kite
-
Name:
- Gilead and Kite
